Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
Recruiting
Phase 2
Interventional Study
Locally Advanced Non-Small Cell Lung Cancer
Thoracic Radiotherapy
Safety
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 44 (estimated)
- Sponsor
- JIANYANG WANG · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Concurrent chemoradiotherapy (cCRT) is the standard treatment for patients with negative epidermal growth factor receptor (EGFR)-mutated unresectable locally advanced non-small cell lung cancer (LA-NSCLC). However, parts of patients only receive sequential chemoradiotherapy (sCRT) due to various reasons. This phase II study aimed to improve the outcomes of patients receiving sCRT by combining anti…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Patients with histologically or cytologically confirmed negative EGFR (including EGFR exon 19 deletion or L858R mutations) or ALK/ROS1-mutated locally advanced unresectable NSCLC were screened.
Inclusion Criteria:
1. ≥18 years old with no restrictions on sex;
2. Peripheral tumor, or central lung c…
Contacts